Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Pfizer and BioNTech are teaming up on a coronavirus vaccine. Photo: Drew Angerer/Getty Images

Patients who received an experimental coronavirus vaccine being developed by Pfizer and BioNTech generated immune responses to the virus, and there were no life-threatening side effects, according to early trial results posted Wednesday and reported by STAT.

The big picture: This particular vaccine is still a long ways away from proving it works and getting federal approval, but it's an encouraging first step that the vaccine appears to trigger an immune system response and is mostly safe.

Go deeper: Pfizer says it won't put "huge price" on coronavirus vaccine

Go deeper

Dave Lawler, author of World
Oct 9, 2020 - World

Europe's coronavirus case counts just keep climbing

Data: Our World in Data; Chart: Andrew Witherspoon/Axios

Europe is now recording far more new coronavirus cases than ever before.

The big picture: One reason is testing. Deaths and hospitalizations remain far below the levels seen in the spring, though they continue to tick upward.

Oct 9, 2020 - Health

HCA to return $1.6 billion in coronavirus bailout funds

HCA's hospitals are closing the books on a profitable Q3, despite the pandemic. Photo: Rusty Russell/Getty Images

HCA Healthcare is giving back $1.6 billion of federal bailout payments and paying back $4.4 billion in Medicare loans early. The money was intended to help hospitals weather the pandemic as patients delayed elective care.

Why it matters: Over the summer, the hospital industry said the pandemic was resulting in "the greatest financial crisis we have ever faced in our history." But HCA expects to report higher revenue and adjusted profits in the third quarter.

Updated Oct 8, 2020 - Politics & Policy

Trump says he won't take part in virtual debate

Photo: Olivier Douliery/Pool/Getty Images

President Trump, who continues to battle a coronavirus infection, told Fox Business' Maria Bartiromo on Thursday that he will not take part in a virtual second presidential debate, with his campaign later saying he would do two in person debates later on this month.

What he's saying: "I'm not going to waste my time on a virtual debate. It’s not what debating is all about. ... It’s ridiculous," the president said.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!